Advancing R/R AML care requires collaboration, innovation, and cutting-edge research. IMPACT-AML provides haematologists with access to clinical trials, real-world data, and a network of experts to drive breakthroughs in treatment and patient outcomes.
Be a part of IMPACT-AML, a pioneering initiative redefining care for Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML). Collaborate with a multidisciplinary consortium to advance groundbreaking therapies, improve patient outcomes, and shape the future of haematology. Together, we can turn challenges into opportunities, delivering hope to patients and their families.
By collaborating with the IMPACT-AML Consortium, haematologists could gain access to state-of-the-art clinical trials, real-world data from STREAM, and a robust platform for joint research. This is your chance to contribute to transformative therapies, setting a new standard for AML care across Europe.
Your expertise is crucial to IMPACT-AML’s success. Join us in this collaborative effort to not only expand scientific understanding, but also to ensure every R/R AML patient has access to optimised, evidence-based care. Let’s make a difference, together.
Access to STREAM and future new opportunities in personalised medicine.
Collaborate with Europe’s leading haematologists and research institutions
Shape therapies that prioritise quality of life and outcomes of our patients and their families
Influence policy and practice at both European and international levels.
Enhance your expertise and contribute to landmark advancements in haematology.